Compare Sana Biotechnology Inc (SANA) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Symbotic Inc — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Symbotic Inc trades at $42.16 (market cap $5.46B). The key difference: Symbotic Inc is far larger — about 6.5× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,965,805). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Symbotic Inc for 23 Days on average.
| SANA | SYM | |
|---|---|---|
Market Cap | $836.71M | $5.46B |
Volume | 4,507,444 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $5.92 | $87.30 |
52-Week Low | $2.68 | $38.22 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $749.96M | $3.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported negative net income of -$16.94M for 2025 despite $2.25B revenue, though 2026 projections show improvement to $8M net profit. Analysts maintain a buy consensus with a $60.33 price target, representing 39% upside potential from current levels.
SYM presents growth potential with a massive $22.5B backlog and expanding robotics/AI market, but faces significant customer concentration risk (85% revenue from Walmart) and recent earnings misses. The stock appears undervalued with a P/E of 1.05, though high EV/EBITDA of 74.05 suggests premium valuation relative to current earnings power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
